Marco Gambarotti, MD

Medical Doctor
Department of Pathology, IRCCS, Istituto Ortopedico Rizzoli
Bologna, Emilia-Romagna, Italy

Head of Anatomy and Pathological Histology Unit of the Rizzoli Orthopaedic Institute. Involved in many national and international research projects and societies, including SIAPEC - IAP, International Skeletal Society, EMSOS (European Musculo-Skeletal Oncology Society), and FOSTER (Fight Osteosarcoma Through European Research) consortium; from June 2021, member of the Board of Directors of the Italian Sarcoma Group (ISG). Author and co-author of more than 120 scientific papers on national or international journals and of some chapters of the last WHO Classifications of Soft Tissue and Bone Tumours and of Paediatric tumours.

Disclosure information not submitted.

Presentation(s):

• RESPONSE TO MIFAMURTIDE AND TUMOR MICROENVIRONMENT: A DECONVOLUTION NANOSTRING ANALYSIS IN LOCALIZED OSTEOSARCOMA PATIENTS TREATED WITHIN THE ISG/OS2 CLINICAL TRIAL

  Wednesday, November 13, 2024
  1:00 PM – 2:45 PM PST

• Paper 19 - IS THERE A ROLE FOR MIFAMURTIDE IN NONMETASTATIC EXTREMITY HIGH-GRADE OSTEOSARCOMA PATIENTS? RESULTS OF PROSPECTIVE ITALIAN SARCOMA GROUP (ISG/OS-2) AND SPANISH SARCOMA GROUP (GEIS-33) TRIALS

  Thursday, November 14, 2024
  1:45 PM – 3:15 PM PST